Skip to main content
main-content

The independent medical news service

14-01-2021 | Oncology | News | Article

Real-world data support efficacy of SABR for extracranial oligometastases

The beneficial survival outcomes and low toxicity associated with stereotactic ablative body radiotherapy in patients with extracranial oligometastases persist in the real-world setting.

26-11-2020 | Oncology | News | Article

Oligometastatic cancer outcomes acceptable with SABR

Stereotactic ablative radiotherapy is associated with “clinically acceptable” rates of toxicity, local control, progression-free survival, and overall survival in people with oligometastatic cancer, meta-analysis data suggest.

12-03-2020 | Oncology | News | Article

Metastases progression linked to deteriorating HRQoL

Disease progression among patients with metastatic lung, pancreatic, colorectal, and breast cancer is associated with statistically significant and clinically relevant reductions in health-related quality of life, real-world study data show.

23-04-2019 | Oncology | News | Article

SABR may improve survival in oligometastatic cancer

The phase II SABR-COMET study has indicated that stereotactic ablative radiotherapy prolongs overall and progression-free survival versus palliative treatment in patients with up to five oligometastases.

01-02-2019 | Colorectal cancer | News | Article

EMA gives biosimilar bevacizumab positive opinion

Read more on this decision here

29-11-2018 | Colorectal cancer | News | Article

Rechallenge with cetuximab, irinotecan may benefit mCRC patients

Approximately one-fifth of patients with RAS and BRAF wild-type metastatic colorectal cancer derive clinical benefit from rechallenge with cetuximab plus irinotecan, Italian researchers report.

Image Credits